Final Analysis of the Phase 3 LITESPARK-011 Study: Belzutifan Plus Lenvatinib Versus Cabozantinib for Advanced Renal Cell Carcinoma After Anti–PD-(L)1 Therapy. Presented by @DrDanielHeng. #ESMO26 written coverage by @rksayyid > https://bit.ly/4zYNuFz #KidneyCancer #RCC @myESMO